Ubs Group Ag Kura Oncology, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 139,525 shares of KURA stock, worth $817,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139,525

Previous 315,475 55.77%

Holding current value

$817,616

Previous $2.75 Million 66.51%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$6.6 - $9.05 $1.16 Million - $1.59 Million	-175,950 Reduced 55.77%	139,525 $920,000
Q4 2024 Feb 14, 2025	BUY	$8.51 - $19.21 $1.58 Million - $3.57 Million	185,659 Added 143.02%	315,475 $2.75 Million
Q3 2024 Nov 14, 2024	BUY	$18.57 - $23.23 $706,384 - $883,645	38,039 Added 41.45%	129,816 $2.54 Million
Q2 2024 Aug 13, 2024	SELL	$17.53 - $22.98 $2.37 Million - $3.1 Million	-135,044 Reduced 59.54%	91,777 $1.89 Million
Q1 2024 May 13, 2024	BUY	$13.42 - $23.53 $320,254 - $561,519	23,864 Added 11.76%	226,821 $4.84 Million
Q4 2023 Feb 09, 2024	BUY	$7.58 - $14.38 $914,238 - $1.73 Million	120,612 Added 146.47%	202,957 $2.92 Million
Q3 2023 Nov 09, 2023	BUY	$8.44 - $11.86 $694,848 - $976,410	82,328 Added 484282.34%	82,345 $750,000
Q2 2023 Aug 11, 2023	SELL	$9.62 - $13.99 $2.06 Million - $3 Million	-214,123 Reduced 99.99%	17 $0
Q1 2023 May 12, 2023	SELL	$10.71 - $14.6 $8,525 - $11,621	-796 Reduced 0.37%	214,140 $2.62 Million
Q4 2022 Feb 08, 2023	BUY	$11.23 - $16.9 $2.04 Million - $3.07 Million	181,705 Added 546.79%	214,936 $2.67 Million
Q3 2022 Nov 10, 2022	SELL	$12.01 - $19.45 $336,484 - $544,930	-28,017 Reduced 45.74%	33,231 $454,000
Q2 2022 Aug 10, 2022	SELL	$10.71 - $18.33 $1.37 Million - $2.34 Million	-127,571 Reduced 67.56%	61,248 $1.12 Million
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $282,861 - $407,723	24,012 Added 14.57%	188,819 $3.04 Million
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $1.87 Million - $3 Million	153,363 Added 1340.12%	164,807 $2.31 Million
Q3 2021 Nov 15, 2021	SELL	$15.42 - $21.72 $33,291 - $46,893	-2,159 Reduced 15.87%	11,444 $214,000
Q2 2021 Aug 13, 2021	SELL	$20.85 - $29.88 $925,656 - $1.33 Million	-44,396 Reduced 76.55%	13,603 $284,000
Q1 2021 May 12, 2021	BUY	$24.75 - $39.14 $1.26 Million - $2 Million	51,012 Added 730.1%	57,999 $1.64 Million
Q4 2020 Feb 11, 2021	BUY	$29.0 - $41.62 $39,237 - $56,311	1,353 Added 24.01%	6,987 $228,000
Q3 2020 Nov 12, 2020	BUY	$16.3 - $30.64 $87,775 - $164,996	5,385 Added 2162.65%	5,634 $173,000
Q2 2020 Jul 31, 2020	SELL	$7.95 - $18.81 $129,592 - $306,621	-16,301 Reduced 98.5%	249 $4,000
Q1 2020 May 01, 2020	SELL	$6.45 - $14.04 $94,292 - $205,250	-14,619 Reduced 46.9%	16,550 $165,000
Q4 2019 Feb 14, 2020	SELL	$12.97 - $15.94 $616,075 - $757,150	-47,500 Reduced 60.38%	31,169 $429,000
Q3 2019 Nov 14, 2019	BUY	$14.75 - $20.87 $1.13 Million - $1.61 Million	76,917 Added 4390.24%	78,669 $1.19 Million
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $25,771 - $34,672	1,752 New	1,752 $35,000
Q1 2019 May 14, 2019	SELL	$13.73 - $16.87 $690,275 - $848,139	-50,275 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$10.6 - $17.49 $458,778 - $756,984	43,281 Added 618.83%	50,275 $705,000
Q3 2018 Nov 14, 2018	BUY	$16.65 - $21.85 $116,450 - $152,818	6,994 New	6,994 $122,000
Q2 2018 Aug 14, 2018	SELL	$14.8 - $18.8 $453,930 - $576,614	-30,671 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$14.5 - $23.4 $263,479 - $425,201	18,171 Added 145.37%	30,671 $575,000
Q4 2017 Feb 14, 2018	SELL	$13.5 - $16.65 $36,504 - $45,021	-2,704 Reduced 17.78%	12,500 $191,000
Q3 2017 Nov 14, 2017	BUY	$6.05 - $14.95 $91,984 - $227,299	15,204 New	15,204 $227,000
Q2 2017 Aug 14, 2017	SELL	N/A	-2,639 Closed	0 $0
Q1 2017 Nov 14, 2017	BUY	N/A	2,639	2,639 $23,000

Others Institutions Holding KURA

# of Institutions

190

Shares Held

79M

Call Options Held

76K

Put Options Held

85.8K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $392M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account